[{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO to Present New Preclinical Data on IL-15 Superagonist, SO-C101, at the 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sotio","sponsor":"Unum Therapeutics","pharmaFlowCategory":"D","amount":"$11.5 million","upfrontCash":"$8.1 million","newsHeadline":"SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CZECH REPUBLIC","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO to Present New Data on the IL-15 superagonist SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sotio","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"$1,027.5 million","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Sotio","sponsor":"PPF Group","pharmaFlowCategory":"D","amount":"$316.5 million","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Secures \u20ac280m of Funding to Expand and Advance Clinical Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sotio","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA\u00ae (Pembrolizumab) in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Presents Interim Data from its Phase 1\/1b Study of SO-C101 in Patients with Advanced Solid Tumors at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Announces Oral and Multiple Poster Presentations on Key Clinical Programs at the American Association of Cancer Research Annual Meeting (AACR) 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Data from the Phase 1\/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oral Presentation of Interim Data from the AURELIO-03 Study of SOT101 at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from SOTIO's Phase 1\/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO to Present the AURELIO-04 Phase 2 Study Design and Findings from BOXR Research at the SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Sotio","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sotio Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Line Gastric and Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Provides Update on Interim Data from Clinical Trials of Nanrilkefusp Alfa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Sotio","sponsor":"Synaffix","pharmaFlowCategory":"D","amount":"$740.0 million","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]
Find Clinical Drug Pipeline Developments & Deals by Sotio
Under the agreement, SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs targeting distinct tumor-associated antigens.
SOT101 (nanrilkefusp alfa) is an IL-15 superagonist that is fused to the sushi+ domain of the IL-15 receptor alpha chain. IL-15 activity increases the number of cytotoxic T cells and NK cells, which shows anti-cancer immune response.
SOT102 is a potent antibody-drug conjugate that combines the clinically-validated target Claudin 18.2 (CLDN18.2) with a powerful toxin to address gastric, pancreatic and other cancers that have very few targeted treatments available.
SOT101 (nanrilkefusp alfa) is a subcutaneously administered IL-15 superagonist that is fused to the sushi+ domain of the IL-15 receptor alpha chain. IL-15 activity increases the number of cytotoxic T cells and NK cells, which shows anti-cancer immune response.
SOT106 is a novel ADC based on SOTIO Biotech’s proprietary antibodies and LCB’s industry-leading ConjuAll™ ADC platform technology with potential best-in class efficacy, safety and tolerability currently in preclinical development against multiple solid tumor indications.
SOT101 (formerly SO-C101) (RLI-15) is a subcutaneously-administered IL-15 superagonist that is fused to the IL-15α chain receptor. SOT101 is designed to selectively bind only to cytotoxic T and NK cells, while avoiding other cell types that are associated with adverse events.
SOT101 (SO-C101) is subcutaneously administered IL-15R superagonist that is fused to sushi+ domain of IL-15 receptor α chain, demonstrated strong preclinical in vivo efficacy in various tumor models showing increased tumor regression, as well as favorable toxicology profile.
The adverse event profile of SOT101 in combination with pembrolizumab was in line with the adverse event profile of either compound as monotherapy. No additive toxicity was seen when combining SOT101 with pembrolizumab.
AURELIO-03 is a Phase 1/1b dose escalation study of SOT101(formerly SO-C101) (RLI-15) is a subcutaneously-administered IL-15 superagonist that is fused to IL-15α chain receptor.as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.
SOT102 is a CLDN18.2 targeting highly specific mAB conjugated to a potent cytotoxic drug molecule, Preclinical data from studies of SOT102 have demonstrated potent anti-tumor efficacy in vitro and in vivo due to NBE’s proprietary site-specific SMAC conjugation platform.